Nausea and Vomiting during pregnancy. Hyperemesis gravidarum, mild or unspecified, starting before the end of the 22nd week of gestation
Conditions
Interventions
Intervention 1: Intervention group: The participants will randomly select to one of four oral treatments groups for one week : Ondansetron (4 mg/twice a day), and Rhizome (250 mg/twice a day) or Vitam
Treatment - Drugs
Placebo
Intervention group: The participants will randomly select to one of four oral treatments groups for one week : Ondansetron (4 mg/twice a day), and Rhizome (250 mg/twice a day) or Vitamin B6 (40 mg/twi
Control group: Prescription Placebo twice a day for one week.
Sponsors
Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age of 18-40 years; Primi Para; No history of psychological illness; non-use of psychological drugs. exclusion criteria: Unwillingness to continue cooperation; Allergy to drug useage.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea and vomiting. Timepoint: Before the intervention and one week after the intervention. Method of measurement: PUQE-24 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of nausea and vomiting. Timepoint: Before the intervention, and one week after the intervention. Method of measurement: PUQE-24 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Shobeiri
Hamadan University of Medical Sciences
Outcome results
None listed